Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HINT1 | P49773 | 4/20 | 0.40 |
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 2/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18024054 | 0.93 | TAAR1 (0.43) | TAAR1HINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL16214975 | 0.85 | AHCY (0.44) | NT5E | |
| SCHEMBL16858617 | 0.83 | ADORA3 (0.48) | HINT1NT5ESTING1 | |
| SCHEMBL16858614 | 0.83 | ADORA3 (0.48) | HINT1NT5ESTING1 | |
| SCHEMBL18072191 | 0.83 | ADORA3 (0.48) | HINT1NT5ESTING1 | |
| SCHEMBL16214090 | 0.83 | ADORA3 (0.48) | HINT1NT5ESTING1 | |
| SCHEMBL18022446 | 0.82 | HINT1 (0.46) | HINT1NT5ESTING1 | |
| SCHEMBL19590280 | 0.79 | TGM2 (0.48) | NT5EKRASPNPSTING1 | |
| SCHEMBL16214185 | 0.79 | TGM2 (0.48) | NT5EKRASPNPSTING1 | |
| SCHEMBL16368349 | 0.79 | TGM2 (0.48) | NT5EKRASPNPSTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237106-A1 | 4'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF EBOLA VIRUS RNA REPLICATION | RIBOSCIENCE LLC (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237106-A1 | 4'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF EBOLA VIRUS RNA REPLICATION | RNMT, RNGTT, EIF2AK2 | TAAR1 2303/4885HINT1 1490/4885NT5E 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.